ClinicalTrials.gg
CompletedNCT02257398Updated Jul 13, 2017

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

A Phase 1 interventional study of GSK2140944 and GSK2140944 placebo in Infections, Respiratory Tract, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Respiratory Tract Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · GlaxoSmithKline.

Enrollment
6th of 19
55 · median 46
Started
2014
with 1 other
Phase 1
14 of 21
none open now
Registered
15th of 21
by date

Among the 21 studies in Respiratory Tract Infections by GlaxoSmithKline, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2014, is one of 14 in phase 1, and was the 15th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 21 studies in Respiratory Tract Infections by GlaxoSmithKline is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Respiratory Tract Infections by GlaxoSmithKline as a file.
02

Study summary

This is Phase I, 4-period, randomized, active-and placebo-controlled, double-blind crossover, single-dose study to evaluate the effects of a therapeutic (1000 milligram [mg]) and supratherapeutic (1800 mg) dose of GSK2140944 with a positive control (moxifloxacin 400 mg) and placebo on the corrected QT interval (QTc) as assessed by continuous 12-lead Holter electrocardiograms (ECGs) in approximately 55 healthy volunteers.

All subjects will receive single doses of GSK2140944 1000 mg, GSK2140944 1800 mg, moxifloxacin 400 mg, and placebo in a randomized sequence. A double-dummy approach will be used to maintain blinding. Thus, on each dosing day, moxifloxacin or moxifloxacin placebo and GSK2140944 or placebo will be administered.

Subjects will be screened within 30 days prior to entry to the clinic. Subjects will report to the clinical unit on Day -2 of Period 1 and on Day -1 in subsequent periods. Subjects will remain confined until check out procedures have been completed on Day 3 (5 days confinement in Period 1 and 4 days in the following 3 periods). There will be a washout of at least 7 days between doses. The follow-up visit will occur 7-10 days after the final dose. Total duration of the study (from screening to the follow-up visit) will be approximately 60 days.

03

Conditions studied

  • Infections, Respiratory Tract

Keywords

  • TQTc
  • Moxifloxacin
  • GSK2140944
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 55 years of age, inclusive, at the time of signing the
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator feels and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Body weight >= 50 kilogram (kg) and within the range 19 to 31 kilogram / square meter (kg/m\^2) (inclusive).
  • A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin test), not lactating, and at least one of the following conditions applies:
  • Nonreproductive potential defined as:
  • Premenopausal females with one of the following: Documented tubal ligation, documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, hysterectomy, documented bilateral oophorectomy.
  • defined as 12 months of spontaneous amenorrhea. To confirm postmenopausal status, a blood sample for simultaneous follicle-stimulating hormone (FSH) >40 milli-international units per mililiter (mlU/mL) and estradiol \<40 picogram/milliliter (pg/mL) (\<147 picomole/liter [pmol/L]) is confirmatory. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrolment.
  • and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study drug and until at least 7 days after the last dose of study drug and completion of the follow-up visit.
  • This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long-term and persistent basis.
  • Contraceptive subdermal implant that meets the standard operating procedure (SOP) effectiveness criteria including a \<1% rate of failure per year, as stated in the product label, intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a \<1% rate of failure per year, as stated in the product label, oral contraceptive, either combined or progestogen alone, injectable progestogen, contraceptive vaginal ring, percutaneous contraceptive patches, male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject.
  • These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
  • Capable of giving signed informed consent as described in protocol, which includes compliance with the requirements and restrictions listed in the consent form and in the protocol
  • (ALT) and \<1.5 × (ULN). Isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%. One repeat test to confirm result is acceptable.
  • Serum potassium, calcium, and magnesium laboratory parameters within normal limits at screening and check-in.

Exclusion criteria

Exclusion Criteria:

  • History/evidence of any arrhythmia (for example, second- or third-degree heart block, atrial fibrillation, supraventricular tachycardia, symptomatic sinus bradycardia, junctional rhythm) or cardiac disease or procedure (mitral valve regurgitation, heart murmur, angina/ischemia, congenital heart abnormalities, coronary artery bypass grafting surgery, or percutaneous transluminal coronary angioplasty). A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, and family history of long syndrome).
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert syndrome or asymptomatic gallstones).
  • Any clinically significant CNS (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic, or GI conditions or history of such conditions that, in the opinion of the investigator, may place the subject at an unacceptable risk as a participant in this trial or may interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • History of photosensitivity to quinolones.
  • Use of systemic antibiotic within 30 days of screening.
  • Confirmed lifetime history of C. difficile diarrhea
  • History of spontaneous tendon rupture
  • History of smoking or use of nicotine containing products within 3 months of screening or a positive urine cotinine indicative of smoking at screening.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams of alcohol: 12 fluid ounces (fl oz) (360 millilitre [mL]) of beer, 5 fl oz (150 mL) of wine, or 1.5 fl oz (45 mL) of 80-proof distilled spirits.
  • History of sensitivity to any of the study drugs or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK medical monitor, contraindicates the potential subject's participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain IV cannula patency).
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening or positive (HIV) antibody.
  • A positive urine test for drugs of abuse at screening or at Day -1; positive urine test for alcohol (or alcohol breath test) within 24 hours of any dose in the study.
  • Exclusion criteria for screening and baseline (a single repeat test is allowed for eligibility determination): Heart rate: \<40 and >100 beats per minute (bpm) (For males), \<45 and >100 bpm (For Females); PR interval\<120 and >220 millisecond (msec); QRS duration\<70 and >110 msec; QTcF interval>450 msec.
  • Evidence of previous myocardial infarction (does not include ST-segment changes associated with repolarization).
  • Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular block [second degree or higher], Wolff-Parkinson-White syndrome), sinus pauses >3 seconds, non-sustained or sustained ventricular tachycardia (>3 consecutive ventricular ectopic beats), or any significant arrhythmia that, in the opinion of the investigator and GSK medical monitor, will interfere with the safety of the individual subject.
  • An abnormal finding of clinical significance in the arrhythmia detection Holter performed on Day -2, which in the view of the investigator would compromise subject safety or interfere with study procedures or assessments will be excluded from the study. Full disclosures will be reviewed in detail and the review maintained as part of the subject's source documents. Analysis of the Holter recordings will consider the following:
  • Heart rate (significant brady- or tachycardia, based on investigator's judgment)
  • Reports of symptomatic arrhythmia (except isolated extrasystoles)
  • Normal and aberrant beats
  • Number of supraventricular contractions, premature atrial contractions, premature ventricular contractions, couplets, triplets, and ventricular tachycardias
  • Atrioventricular conduction defects
  • Atrial fibrillation and flutter
  • Participation in the study would result in a donation of blood or blood products in excess of 500 mL within a 56-day period.
  • Participation in a clinical trial in which the subject has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Sequence ABDC

    Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes

    Drug: GSK2140944 · Drug: GSK2140944 placebo · Drug: Moxifloxacin · Drug: Moxifloxacin placebo

  • Experimental
    Sequence BCAD

    Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes

    Drug: GSK2140944 · Drug: GSK2140944 placebo · Drug: Moxifloxacin · Drug: Moxifloxacin placebo

  • Experimental
    Sequence CDBA

    Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes

    Drug: GSK2140944 · Drug: GSK2140944 placebo · Drug: Moxifloxacin · Drug: Moxifloxacin placebo

  • Experimental
    Sequence DACB

    Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes

    Drug: GSK2140944 · Drug: GSK2140944 placebo · Drug: Moxifloxacin · Drug: Moxifloxacin placebo

Interventions

  • GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution

  • DrugGSK2140944 placebo

    GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.

  • Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.

  • DrugMoxifloxacin placebo

    Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.

06

What researchers measure

Primary outcomes

  1. Change from baseline in corrected QT interval, using the Fridericia formula (QTcF) for GSK2140944 (1000 mg and 1800 mg)

    ECGs will be measured using a 24-hour continuous 12-lead Holter monitor. ECGs will be extracted up to 10 replicates at the following time points: at 3 time points pre-dose (45, 30, and 15 minutes prior to starting the infusion) and 0.25, 0.5, 1.0, 1.5, 2.0 (end of infusion), 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24 and 48 hours after dosing, for a total of 16 time points per treatment period

    Time frame: Up to 48 hours

Secondary outcomes

  1. Change from baseline in ECG parameters for GSK2140944 (1000 mg and 1800 mg)

    ECGs will be measured using a 24-hour continuous 12-lead Holter monitor at predefined timepoints. ECG parameters includes QT (QT interval), QT corrected according to the Bazett formula (QTcB), QT/RR pairs from the defined time points at which subjects are supinely resting (QTci), Individually corrected QT interval (QTcI), heart rate (HR), PR interval, and the complex of 3 of the graphical deflections seen on a typical ECG (QRS) interval

    Time frame: Up to 48 hours

  2. Categorical outliers in ECG parameters for GSK2140944 (1000 mg and 1800 mg)

    ECGs will be measured using a 24-hour continuous 12-lead Holter monitor at predefined time points. Categorical outliers ECG parameters includes QTc, HR, PR, and QRS interval

    Time frame: Up to 48 hours

  3. Change from baseline in ECG parameters for moxifloxacin

    ECGs will be measured using a 24-hour continuous 12-lead Holter monitor at predefined time points. ECG parameters includes QTcF, QTcB, QTci, QTcI, QT, HR, PR, and QRS interval

    Time frame: Up to 48 hours

  4. Composite of pharmacokinetic (PK) parameters for GSK2140944 (1000 mg and 1800 mg)

    PK parameters including area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC\[0-infinity\]), area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC\[0-t\]), systemic clearance of parent drug (CL), maximum observed concentration (Cmax)

    Time frame: Up to 48 hours

  5. Composite of PK parameters for moxifloxacin

    PK parameters including AUC(0-infinity), AUC(0-t), CL, apparent clearance of parent drug after oral dosing (CL/F), Cmax, λz, t1/2, tmax, Vss, Vz, apparent volume of distribution after oral dosing (Vz/F).

    Time frame: Up to 48 hours

  6. Plasma concentrations and change in QTcF for GSK2140944 and moxifloxacin

    The relationship between GSK2140944 plasma concentration following single IV administration and the baseline adjusted QTcF interval corrected for placebo will be explored

    Time frame: Up to 48 hours

  7. Amount excreted (Ae) in urine of unchanged GSK2140944 (1000 mg and 1800 mg)

    Urinary recovery of unchanged drug that is total amount of drug excreted in urine (Ae), calculated by adding all the fractions of drug collected over all the allotted time intervals

    Time frame: Up to 48 hours

  8. Fraction of the dose (fe) excreted in urine

    Fraction of the dose (fe) will be calculated as, percentage fe= (Ae/Dose) × 100

    Time frame: Up to 48 hours

  9. Renal clearance

    Renal clearance of drug will be calculated as: Ae/ AUC(0-t)

    Time frame: Up to 48 hours

  10. Assessment of ECG

    Single 12-lead safety ECGs will be obtained at predefined time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals

    Time frame: Up to Day 48

  11. Change from baseline in vital sign measurements

    Vital signs includes temperature, systolic and diastolic blood pressure and pulse rate and respiratory rate

    Time frame: Up to Day 48

  12. Number of subjects with adverse events (AEs)

    An AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

    Time frame: Up to Day 48

  13. Toxicity grading of clinical laboratory test results

    Clinical laboratory parameters includes hematology, clinical chemistry, and urinalysis

    Time frame: Up to Day 48

07

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
08

References and documents

Publications

  • Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02385-16. doi: 10.1128/AAC.02385-16. Print 2017 May. PubMed 28223381 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Mar 2015, 4 months.

Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 6, 2014
StartActual
Oct 6, 2014
Primary completionActual
Mar 2, 2015
CompletionActual
Mar 2, 2015
Last update
Jul 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02257398
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 6, 2014
Start date
Oct 6, 2014
Primary completion
Mar 2, 2015
Completion
Mar 2, 2015
Last update
Jul 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion